{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:33:38Z","timestamp":1788348818936,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"DOI":"10.1186\/s12936-026-05857-5","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T14:46:29Z","timestamp":1777041989000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Therapeutic efficacy of artemether-lumefantrine and molecular markers of antimalarial drug resistance in Benin, 2022"],"prefix":"10.1186","volume":"25","author":[{"given":"Irene","family":"Cavros","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augustin","family":"Kpemasse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis Sacca Yarou","family":"Maye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramani","family":"Saliou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakariahou","family":"Kpanou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Houndjo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Aissan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyriaque Dossou","family":"Affoukou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davy","family":"Yamonmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Affoukou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alla","family":"Zlochevska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Awa Bineta","family":"Deme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamadou Alpha","family":"Diallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassirou","family":"Ngom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A\u00efta","family":"Sene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djiby","family":"Sow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Condo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virgile","family":"Gnanguenon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Saadani","family":"Hassani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurore Ogouyemi","family":"Hounto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"key":"5857_CR1","unstructured":"World malaria report 2025: Addressing the threat of antimalarial drug resistance."},{"key":"5857_CR2","unstructured":"Republic of Benin Ministry of Health. Health Management Information System (HMIS) data. 2022."},{"key":"5857_CR3","unstructured":"Republic of Benin National Malaria Control Program. National Malaria Treatment Guidelines. 2020."},{"key":"5857_CR4","unstructured":"WHO. Methods for surveillance of antimalarial drug efficacy. 2009. https:\/\/www.who.int\/publications-detail-redirect\/9789241597531. Accessed 14 Apr 2024."},{"issue":"1","key":"5857_CR5","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12936-016-1091-2","volume":"15","author":"A Ogouy\u00e8mi-Hounto","year":"2016","unstructured":"Ogouy\u00e8mi-Hounto A, Azandossessi C, Lawani S, et al. Therapeutic efficacy of artemether\u2013lumefantrine for the treatment of uncomplicated falciparum malaria in northwest Benin. Malar J. 2016;15(1):37. https:\/\/doi.org\/10.1186\/s12936-016-1091-2.","journal-title":"Malar J"},{"issue":"3","key":"5857_CR6","doi-asserted-by":"publisher","first-page":"670","DOI":"10.4269\/ajtmh.21-0086","volume":"105","author":"A Kpemasse","year":"2021","unstructured":"Kpemasse A, Dagnon F, Saliou R, et al. Efficacy of artemether-lumefantrine for the treatment of *Plasmodium falciparum* malaria in Bohicon and Kandi, Republic of Benin, 2018\u20132019. Am J Trop Med Hyg. 2021;105(3):670\u20136. https:\/\/doi.org\/10.4269\/ajtmh.21-0086.","journal-title":"Am J Trop Med Hyg"},{"issue":"1","key":"5857_CR7","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s12936-022-04182-x","volume":"21","author":"MM Plucinski","year":"2022","unstructured":"Plucinski MM, Ashley EA, Bassat Q, Venkatesan M, Rosenthal PJ, Halsey ES. STARTER checklist for antimalarial therapeutic efficacy reporting. Malar J. 2022;21(1):187. https:\/\/doi.org\/10.1186\/s12936-022-04182-x.","journal-title":"Malar J"},{"key":"5857_CR8","unstructured":"Coartem (Artemether and Lumefantrine) Tablets, for Oral Use. Prescribing Information. Novartis Pharmaceuticals Corporation. 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/022268s017lbl.pdf. Accessed 20 Apr 2026."},{"key":"5857_CR9","unstructured":"Informal Consultation on Methodology to Distinguish Reinfection from Recrudescence in High Malaria Transmission Areas: Report of a Virtual Meeting, 17\u201318 May 2021. 1st ed. World Health Organization; 2021."},{"key":"5857_CR10","doi-asserted-by":"crossref","unstructured":"Talundzic E et al. Next-generation sequencing and bioinformatics protocol for malaria drug resistance marker surveillance. Antimicrobial Agents and Chemotherapy. 2018;62(4):e02474\u201317.","DOI":"10.1128\/AAC.02474-17"},{"issue":"3","key":"5857_CR11","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.ijpddr.2016.08.004","volume":"6","author":"MC Oguike","year":"2016","unstructured":"Oguike MC, Falade CO, Shu E, et al. Molecular determinants of sulfadoxine-pyrimethamine resistance in *Plasmodium falciparum* in Nigeria and the regional emergence of dhps 431V. Int J Parasitol Drugs Drug Resist. 2016;6(3):220\u20139. https:\/\/doi.org\/10.1016\/j.ijpddr.2016.08.004.","journal-title":"Int J Parasitol Drugs Drug Resist"},{"issue":"1","key":"5857_CR12","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12936-021-03605-5","volume":"20","author":"SS Svigel","year":"2021","unstructured":"Svigel SS, Adeothy A, Kpemasse A, et al. Low prevalence of highly sulfadoxine\u2010resistant dihydropteroate synthase alleles in *Plasmodium falciparum* isolates in Benin. Malar J. 2021;20(1):72. https:\/\/doi.org\/10.1186\/s12936-021-03605-5.","journal-title":"Malar J"},{"issue":"1","key":"5857_CR13","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12936-023-04487-5","volume":"22","author":"AJ Adegbola","year":"2023","unstructured":"Adegbola AJ, Ijarotimi OA, Ubom AE, et al. A snapshot of the prevalence of dihydropteroate synthase-431V mutation and other sulfadoxine-pyrimethamine resistance markers in *Plasmodium falciparum* isolates in Nigeria. Malar J. 2023;22(1):71. https:\/\/doi.org\/10.1186\/s12936-023-04487-5.","journal-title":"Malar J"},{"issue":"10","key":"5857_CR14","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1093\/jac\/dky258","volume":"73","author":"NP Mandoko","year":"2018","unstructured":"Mandoko NP, Rouvier F, Kakina ML, et al. Prevalence of *Plasmodium falciparum* parasites resistant to sulfadoxine\/pyrimethamine in the Democratic Republic of the Congo: emergence of highly resistant pfdhfr\/pfdhps alleles. J Antimicrob Chemother. 2018;73(10):2704\u201315. https:\/\/doi.org\/10.1093\/jac\/dky258.","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"5857_CR15","doi-asserted-by":"publisher","first-page":"2566","DOI":"10.1093\/jac\/dkv160","volume":"70","author":"P Chauvin","year":"2015","unstructured":"Chauvin P, Menard S, Iriart X, et al. Prevalence of *Plasmodium falciparum* parasites resistant to sulfadoxine\/pyrimethamine in pregnant women in Yaound\u00e9, Cameroon: emergence of highly resistant pfdhfr \/ pfdhps alleles. J Antimicrob Chemother. 2015;70(9):2566\u201371. https:\/\/doi.org\/10.1093\/jac\/dkv160.","journal-title":"J Antimicrob Chemother"},{"key":"5857_CR16","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.ijid.2021.04.081","volume":"107","author":"M L\u2019Episcopia","year":"2021","unstructured":"L\u2019Episcopia M, Kelley J, Dongho DBG, et al. Targeted deep amplicon sequencing of antimalarial resistance markers in *Plasmodium falciparum* isolates from Cameroon. Int J Infect Dis. 2021;107:234\u201341. https:\/\/doi.org\/10.1016\/j.ijid.2021.04.081.","journal-title":"Int J Infect Dis"},{"issue":"3","key":"5857_CR17","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S1473-3099(22)00593-X","volume":"23","author":"KB Beshir","year":"2023","unstructured":"Beshir KB, Muwanguzi J, Nader J, et al. Prevalence of *Plasmodium falciparum* haplotypes associated with resistance to sulfadoxine\u2013pyrimethamine and amodiaquine before and after upscaling of seasonal malaria chemoprevention in seven African countries: a genomic surveillance study. Lancet Infect Dis. 2023;23(3):361\u201370. https:\/\/doi.org\/10.1016\/S1473-3099(22)00593-X.","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"5857_CR18","doi-asserted-by":"publisher","first-page":"3405","DOI":"10.1128\/AAC.00024-09","volume":"53","author":"CJ Sutherland","year":"2009","unstructured":"Sutherland CJ, Fifer H, Pearce RJ, et al. Novel pfdhps haplotypes among imported cases of Plasmodium falciparum malaria in the United Kingdom. Antimicrob Agents Chemother. 2009;53(8):3405\u201310. https:\/\/doi.org\/10.1128\/AAC.00024-09.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"5857_CR19","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12936-021-03585-6","volume":"20","author":"A Gansan\u00e9","year":"2021","unstructured":"Gansan\u00e9 A, Moriarty LF, M\u00e9nard D, et al. Anti-malarial efficacy and resistance monitoring of artemether-lumefantrine and dihydroartemisinin-piperaquine shows inadequate efficacy in children in Burkina Faso, 2017\u20132018. Malar J. 2021;20(1):48. https:\/\/doi.org\/10.1186\/s12936-021-03585-6.","journal-title":"Malar J"},{"issue":"1","key":"5857_CR20","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1186\/s12936-021-03760-9","volume":"20","author":"Y Diarra","year":"2021","unstructured":"Diarra Y, Kon\u00e9 O, Sangar\u00e9 L, et al. Therapeutic efficacy of artemether\u2013lumefantrine and artesunate\u2013amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Mali, 2015\u20132016. Malar J. 2021;20(1):235. https:\/\/doi.org\/10.1186\/s12936-021-03760-9.","journal-title":"Malar J"},{"key":"5857_CR21","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ijpddr.2021.06.001","volume":"16","author":"L Ndwiga","year":"2021","unstructured":"Ndwiga L, Kimenyi KM, Wamae K, et al. A review of the frequencies of Plasmodium falciparum Kelch 13 artemisinin resistance mutations in Africa. Int J Parasitol Drugs Drug Resist. 2021;16:155\u201361. https:\/\/doi.org\/10.1016\/j.ijpddr.2021.06.001.","journal-title":"Int J Parasitol Drugs Drug Resist"},{"issue":"4","key":"5857_CR22","doi-asserted-by":"publisher","first-page":"e82","DOI":"10.1016\/S1473-3099(20)30493-X","volume":"21","author":"NK Kayiba","year":"2021","unstructured":"Kayiba NK, Yobi DM, Tshibangu-Kabamba E, et al. Spatial and molecular mapping of Pfkelch13 gene polymorphism in Africa in the era of emerging Plasmodium falciparum resistance to artemisinin: a systematic review. Lancet Infect Dis. 2021;21(4):e82\u201392. https:\/\/doi.org\/10.1016\/S1473-3099(20)30493-X.","journal-title":"Lancet Infect Dis"},{"issue":"13","key":"5857_CR23","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1056\/NEJMoa2210956","volume":"389","author":"S Mihreteab","year":"2023","unstructured":"Mihreteab S, Platon L, Berhane A, et al. Increasing prevalence of artemisinin-resistant HRP2-negative malaria in Eritrea. N Engl J Med. 2023;389(13):1191\u2013202. https:\/\/doi.org\/10.1056\/NEJMoa2210956.","journal-title":"N Engl J Med"},{"issue":"8","key":"5857_CR24","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/S1473-3099(21)00142-0","volume":"21","author":"A Uwimana","year":"2021","unstructured":"Uwimana A, Umulisa N, Venkatesan M, et al. Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study. Lancet Infect Dis. 2021;21(8):1120\u20138. https:\/\/doi.org\/10.1016\/S1473-3099(21)00142-0.","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"5857_CR25","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1093\/infdis\/jiab352","volume":"225","author":"J Straimer","year":"2022","unstructured":"Straimer J, Gandhi P, Renner KC, Schmitt EK. High prevalence of Plasmodium falciparum K13 mutations in Rwanda is associated with slow parasite clearance after treatment with artemether-lumefantrine. J Infect Dis. 2022;225(8):1411\u20134. https:\/\/doi.org\/10.1093\/infdis\/jiab352.","journal-title":"J Infect Dis"},{"key":"5857_CR26","doi-asserted-by":"publisher","unstructured":"Ishengoma DS, Mandara CI, Bakari C, et al. Evidence of artemisinin partial resistance in North-western Tanzania: clinical and drug resistance markers study. medRxiv. February 1, 2024:2024.01.31.24301954. https:\/\/doi.org\/10.1101\/2024.01.31.24301954.","DOI":"10.1101\/2024.01.31.24301954"},{"issue":"13","key":"5857_CR27","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1056\/NEJMoa2101746","volume":"385","author":"B Balikagala","year":"2021","unstructured":"Balikagala B, Fukuda N, Ikeda M, et al. Evidence of artemisinin-resistant malaria in Africa. N Engl J Med. 2021;385(13):1163\u201371. https:\/\/doi.org\/10.1056\/NEJMoa2101746.","journal-title":"N Engl J Med"},{"issue":"1","key":"5857_CR28","doi-asserted-by":"publisher","first-page":"6353","DOI":"10.1038\/s41467-022-33873-x","volume":"13","author":"PK Tumwebaze","year":"2022","unstructured":"Tumwebaze PK, Conrad MD, Okitwi M, et al. Decreased susceptibility of Plasmodium falciparum to both dihydroartemisinin and lumefantrine in northern Uganda. Nat Commun. 2022;13(1):6353. https:\/\/doi.org\/10.1038\/s41467-022-33873-x.","journal-title":"Nat Commun"},{"issue":"8","key":"5857_CR29","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa2211803","volume":"389","author":"MD Conrad","year":"2023","unstructured":"Conrad MD, Asua V, Garg S, et al. Evolution of partial resistance to artemisinins in malaria parasites in Uganda. N Engl J Med. 2023;389(8):722\u201332. https:\/\/doi.org\/10.1056\/NEJMoa2211803.","journal-title":"N Engl J Med"},{"issue":"10","key":"5857_CR30","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1038\/s41564-023-01461-4","volume":"8","author":"AA Fola","year":"2023","unstructured":"Fola AA, Feleke SM, Mohammed H, et al. Plasmodium falciparum resistant to artemisinin and diagnostics have emerged in Ethiopia. Nat Microbiol. 2023;8(10):1911\u20139. https:\/\/doi.org\/10.1038\/s41564-023-01461-4.","journal-title":"Nat Microbiol"},{"key":"5857_CR31","doi-asserted-by":"publisher","unstructured":"Juliano JJ, Giesbrecht DJ, Simkin A, et al. Country wide surveillance reveals prevalent artemisinin partial resistance mutations with evidence for multiple origins and expansion of high level sulfadoxine-pyrimethamine resistance mutations in northwest Tanzania. Infectious Diseases (except HIV\/AIDS). Preprint posted online November 8, 2023. https:\/\/doi.org\/10.1101\/2023.11.07.23298207.","DOI":"10.1101\/2023.11.07.23298207"},{"key":"5857_CR32","doi-asserted-by":"publisher","unstructured":"Brhane BG, Fola AA, Nigussie H, et al. Rising prevalence of Plasmodium falciparum artemisinin resistance mutations in Ethiopia. medRxiv. Preprint posted online September 13, 2024:2024.09.11.24313421. https:\/\/doi.org\/10.1101\/2024.09.11.24313421.","DOI":"10.1101\/2024.09.11.24313421"},{"issue":"12","key":"5857_CR33","doi-asserted-by":"publisher","first-page":"e1013771","DOI":"10.1371\/journal.ppat.1013771","volume":"21","author":"AJ Zeleke","year":"2025","unstructured":"Zeleke AJ, Fola AA, Tollefson GA, et al. High prevalence and emerging positive association of kelch13 R622I and HRP2-based RDT negativity in Plasmodium falciparum in northern Ethiopia. PLoS Pathog. 2025;21(12):e1013771. https:\/\/doi.org\/10.1371\/journal.ppat.1013771.","journal-title":"PLoS Pathog"},{"key":"5857_CR34","doi-asserted-by":"publisher","unstructured":"Zeleke AJ, Fola AA, Tollefson GA, et al. Artemisinin resistant kelch13 R622I and RDT negativity approaching predominance in northern Ethiopia and emerging C580Y of African origin threaten falciparum malaria control.https:\/\/doi.org\/10.1101\/2025.06.23.25330019","DOI":"10.1101\/2025.06.23.25330019"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-026-05857-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-026-05857-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-026-05857-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T11:47:12Z","timestamp":1779882432000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12936-026-05857-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5857"],"URL":"https:\/\/doi.org\/10.1186\/s12936-026-05857-5","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]},"assertion":[{"value":"30 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"230"}}